MedImmune has entered into a research collaboration with Immunocore to develop novel cancer therapies.
p>MedImmune, the biologics R&D arm of AstraZeneca, has entered into a cancer research collaboration with UK-based biotech company Immunocore. Under the terms of the licensing agreement, both companies will conduct research to develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. The platform harnesses the patient’s immune system by directing T cells to target and destroy cancerous cells without damaging healthy cells. Immunocore and MedImmune will work together to generate ImmTACs against selected cancer targets.
AstraZeneca and MedImmune will have rights to further develop and commercialize ImmTAC products. Immunocore will receive an upfront payment of $20 million per program and is eligible to receive up to $300 million in development and commercial milestone payments for each target program and significant tiered royalties from successful programs.
